-
公开(公告)号：US20230398228A1
公开(公告)日：2023-12-14
申请号：US18062996
申请日：2022-12-07
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Earl F. Albone , Xin Cheng , Daniel W. Custar , Keiji Furuuchi , Jing Li , Utpal Majumder , Toshimitsu Uenaka
IPC: A61K47/68 , C07K16/30 , A61K31/357 , C07K16/28 , C07K16/32
CPC classification number: A61K47/6803 , C07K16/30 , A61K47/6889 , A61K47/6849 , A61K31/357 , C07K16/28 , C07K16/32 , C07K2317/14 , C07K2317/40 , C07K2317/565 , C07K2317/77 , C07K2317/92
Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.
-
公开(公告)号：US20200297860A1
公开(公告)日：2020-09-24
申请号：US16702720
申请日：2019-12-04
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Earl F. Albone , Xin Cheng , Daniel W. Custar , Keiji Furuuchi , Jing Li , Utpal Majumder , Toshimitsu Uenaka
IPC: A61K47/68 , C07K16/30 , A61K31/357 , C07K16/28 , C07K16/32
Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.
-
公开(公告)号：US20190315754A1
公开(公告)日：2019-10-17
申请号：US16391882
申请日：2019-04-23
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Wanjun Zheng , Xiaojie Zhu , Hong Du , Maarten Postema , Yimin Jiang , Jing Li , Robert Yu , Hyeong-wook Choi , Jaemoon Lee , Frank Fang , Daniel Custar
IPC: C07D487/04 , C07D519/00 , A61P35/00
Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
-
公开(公告)号：US10214539B2
公开(公告)日：2019-02-26
申请号：US15787268
申请日：2017-10-18
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Charles E. Chase , Atsushi Endo , Francis G. Fang , Jing Li
IPC: C07D493/20 , C07D307/28 , C07D307/33 , C07D493/08 , C07D493/18 , C07D493/04 , C07D493/22 , C07D307/20 , C07D307/26 , C07D309/16 , C07D405/06 , C07D405/14
Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
-
公开(公告)号：US09604993B2
公开(公告)日：2017-03-28
申请号：US14624033
申请日：2015-02-17
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Charles E. Chase , Atsushi Endo , Francis G. Fang , Jing Li
IPC: C07D493/20 , A61K31/335 , C07D307/28 , C07D307/33 , C07D493/08 , C07D493/18
CPC classification number: C07D493/20 , C07D307/20 , C07D307/26 , C07D307/28 , C07D307/33 , C07D309/16 , C07D405/06 , C07D405/14 , C07D493/04 , C07D493/08 , C07D493/18 , C07D493/22 , Y02P20/55
Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
-
Patent Agency Ranking
公开(公告)号：US11434246B2
公开(公告)日：2022-09-06
申请号：US17141557
申请日：2021-01-05
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Wanjun Zheng , Xiaojie Zhu , Hong Du , Maarten Postema , Yimin Jiang , Jing Li , Robert Yu , Hyeong-Wook Choi , Jaemoon Lee , Francis G. Fang , Daniel Custar
IPC: C07D487/04 , C07D519/00 , A61P35/00
Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
-
公开(公告)号：US10941148B2
公开(公告)日：2021-03-09
申请号：US16391882
申请日：2019-04-23
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Wanjun Zheng , Xiaojie Zhu , Hong Du , Maarten Postema , Yimin Jiang , Jing Li , Robert Yu , Hyeong-wook Choi , Jaemoon Lee , Frank Fang , Daniel Custar
IPC: C07D487/04 , C07D519/00 , A61P35/00
Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
-
公开(公告)号：US10717743B2
公开(公告)日：2020-07-21
申请号：US16284405
申请日：2019-02-25
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Charles E. Chase , Atsushi Endo , Francis G. Fang , Jing Li
IPC: C07D493/20 , C07D307/28 , C07D307/33 , C07D493/08 , C07D493/18 , C07D493/04 , C07D493/22 , C07D307/20 , C07D307/26 , C07D309/16 , C07D405/06 , C07D405/14
Abstract: Methods of synthesizing intermediates useful for the synthesis of halichondrin B analogs are described.
-
公开(公告)号：US10322192B2
公开(公告)日：2019-06-18
申请号：US15892921
申请日：2018-02-09
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Earl F. Albone , Xin Cheng , Daniel W. Custar , Keiji Furuuchi , Jing Li , Utpal Majumder , Toshimitsu Uenaka
IPC: A61K47/68 , C07K16/28 , C07K16/30 , C07K16/32 , A61K31/357
Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.
-
公开(公告)号：US20180305362A1
公开(公告)日：2018-10-25
申请号：US15768668
申请日：2016-10-14
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Wanjun Zheng , Xiaojie Zhu , Hong Du , Maarten Postema , Yimin Jiang , Jing Li , Robert Yu , Hyeong-wook Choi , Jaemoon Lee , Frank Fang , Daniel Custar
IPC: C07D487/04 , C07D519/00 , A61P35/00
CPC classification number: C07D487/04 , A61P35/00 , C07D519/00
Abstract: We provide compounds given by Formula I, which is shown in FIG. 3, or pharmaceutically acceptable salts thereof, as well as formulations thereof and methods of use of those compounds and formulations for treatment of cancer.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.03 seconds)
